A Phase Ⅳ Study of Decitabine in Myelodysplastic Syndrome
The purpose of this study is to evaluate of the safety and efficacy of decitabine treatment of Myelodysplastic Syndrome.
Myelodysplastic Syndrome
DRUG: Decitabine Injection
The safety and efficacy of decitabine treatment of Myelodysplastic Syndrome., The primary efficacy evaluation: ORR The secondary efficacy evaluation: CR，mCR，PR，HI, PFS in one year, Cytogenetic response, transfusion requirements, et al., 2-4 months
Total subjects: 240, doseⅠgroup of 120 patients, doseⅡgroup of 120 patients. Subjects are stratified randomize. If necessary, participants accepted best supportive therapy.